Cartilage Tissue Production Using Copolymer Substrate Spots
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing cartilage tissue from stem cells face challenges in mass-producing high-efficiency, uniform cartilage regenerating materials due to the lack of specification at intermediate stages, such as human cartilage progenitor cells, which hinders efficient and cost-effective production of cartilage tissue.
Innovation Solution
A method involving a substrate with specific copolymer spots to culture human cartilage progenitor cells, inducing cartilage differentiation under controlled conditions using Wnt and TGFβ signal activation, and culturing in an agar-containing medium to produce cartilage tissue without non-cartilage cells, allowing for efficient growth and large tissue production from a small cell number.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous cultured cartilage tissue transplantation is used, then cartilage tissue can be produced for transplantation, but patient burden increases due to requiring two operations (cartilage collection and cultured cartilage transplantation)
Solution Approach 1:
The patent introduces an intermediary substrate with specific copolymer spots that mediates the transformation of stem cells into cartilage tissue. The substrate acts as a controlled environment that guides cell differentiation and aggregation, eliminating the need for autologous cartilage collection while maintaining transplantation efficacy.
Solution Approach 2:
The patent changes the chemical parameters of the substrate surface by using specific copolymers with controlled hydrophilicity and cell adhesion properties. This parameter change enables controlled cell aggregation and differentiation without requiring autologous cartilage, thereby reducing patient burden while maintaining tissue quality.
2Reliability
If stem cells are cultured to produce cartilage tissue without specifying intermediate stages, then cartilage tissue can be produced, but mass production efficiency and tissue uniformity decrease
Solution Approach 1:
The patent segments the cartilage production process into distinct stages by specifying intermediate cartilage progenitor cells. This segmentation allows for controlled expansion of progenitor cells before final cartilage differentiation, enabling mass production while maintaining tissue uniformity and quality.
Solution Approach 2:
The patent performs preliminary action by first generating and expanding cartilage progenitor cells before inducing final cartilage differentiation. This preliminary expansion stage allows for scaling up cell numbers efficiently, improving productivity while ensuring uniform tissue production through controlled differentiation protocols.
3Reliability
If stem cells are differentiated without specifying intermediate cartilage progenitor cells, then cartilage tissue can be produced, but tissue shape uniformity and property consistency become difficult to control
Solution Approach 1:
The patent applies local quality by creating specific microenvironments on the substrate with copolymer spots that have controlled cell adhesion properties. These localized regions guide uniform cell aggregation and differentiation, ensuring consistent tissue shape and properties across the entire culture area.
Solution Approach 2:
The patent controls manufacturing precision by changing physical and chemical parameters of the culture system, including substrate surface properties, copolymer composition, and culture conditions. These parameter changes ensure uniform cell behavior and consistent cartilage tissue production with controlled shape and properties.
Data Source
AI summary
The present invention is to provide a method for producing a cartilage tissue which comprises a step of providing a substrate for producing cell aggregates provided with a plurality of spots comprising a copolymer containing recurring units derived from monomers represented by the following formulae (I) and (II):[wherein Ua1, Ua, Ra1, Ra2 and Rb are as described in the specification and claims] on a substrate having an ability to suppress adhesion of cells; a step of seeding human cartilage progenitor cells which are positive for PRRX1 protein and derived from pluripotent stem cells on the substrate; a step of producing cell aggregates by culturing the cells; and a step of culturing the aggregates to produce a cartilage tissue.